Dark

Check out our Dark Pool Levels

KMPH
KemPharm, Inc. Common Stock
stock NASDAQ

Inactive

Feb 28, 2023

5.81USD-0.343%(-0.02)64,126

Pre-market

0.00USD-100.000%(-5.83)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 31, 2022

10:29AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 Benzinga

07:20AM EST HC Wainwright & Co. Upgrades KemPharm to Buy, Raises Price Target to $11 Benzinga

Jan 20, 2022

07:01AM EST KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder Benzinga

Jan 19, 2022

04:22PM EST KemPharm CEO Sends Shareholder Letter, Highlights Strategic Focus Benzinga

04:22PM EST KemPharm to Advance KP1077 for Idiopathic Hypersomnia as Lead SDX Product Candidate GlobeNewswire Inc

Jan 12, 2022

07:30AM EST Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, January 19, 2022 at 4:30 p.m. ET GlobeNewswire Inc

Jan 11, 2022

07:30AM EST Data highlight key pharmacokinetic properties of serdexmethylphenidate that are instrumental to its consistent and smooth release of d-MPH GlobeNewswire Inc

Jan 6, 2022

07:30AM EST KemPharm, Inc.(NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the company is participating in BIO Partnering @ JPM, which is being held virtually alongside the J.P. Morgan 40th Annual Healthcare Conference 2022. GlobeNewswire Inc

Jan 4, 2022

07:55AM EST KemPharm Granted U.S. Patent #11,214,544 'Dextrorphan prodrugs and processes for making and using them' Benzinga

Dec 20, 2021

07:49AM EST KemPharm Board Authorizes A Program To Repurchase Up To $50 Mln Of Stock RTTNews

07:32AM EST KemPharm, Inc. Announces Authorization Of $50M Buyback Benzinga

07:30AM EST KemPharm, Inc. Announces Authorization of $50 Million Share GlobeNewswire Inc

Dec 14, 2021

07:34AM EST KemPharm, Inc. Announces Top-Line Results From Clinical Trial Evaluating Safety And Pharmacokinetics Of Higher-Dose SDX; Says Serdexmethylphenidate Delivered At Higher Doses Is Well Tolerated Benzinga

07:30AM EST Data reveal serdexmethylphenidate (SDX) delivered at doses higher than those studied with AZSTARYS is well-tolerated, yields dose-proportional d-MPH exposure, and produces targeted biological effects GlobeNewswire Inc

Dec 13, 2021

04:07PM EST KemPharm To Be Added To Nasdaq Biotech Index, Effective Dec. 20, 2021 Benzinga

04:05PM EST KemPharm to be Added to the Nasdaq Biotechnology Index Effective GlobeNewswire Inc

07:30AM EST KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida GlobeNewswire Inc

Nov 10, 2021

05:31PM EST KemPharm Q3 EPS $(0.05) Beats $(0.07) Estimate, Sales $2.00M Miss $2.18M Estimate Benzinga

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 5, 2021

07:30AM EDT Data demonstrate efficacy of AZSTARYS in children, including 30-minute onset of action and 13-hour duration of effect GlobeNewswire Inc

Nov 3, 2021

09:22AM EDT Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, November 10, 2021, 4:30 p.m. ET GlobeNewswire Inc

Oct 29, 2021

06:14AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 05.45 A.M. EDT). RTTNews

Oct 27, 2021

07:30AM EDT Pharmacokinetic data from two clinical studies of AZSTARYS demonstrated its rapid onset of action and long duration of effect GlobeNewswire Inc

Oct 20, 2021

07:36AM EDT KemPharm Announces Research Involving AZSTARYS And Serdexmethylphenidate To Be Featured In Poster Presentations At Multiple Medical Conferences During ADHD Awareness Month Benzinga

07:30AM EDT KemPharm Announces Research Involving AZSTARYS and GlobeNewswire Inc

Oct 19, 2021

07:30AM EDT Trading to commence effective with the open of business on October 19, 2021 GlobeNewswire Inc

Sep 27, 2021

07:37AM EDT KemPharm To Present At Benzinga Healthcare Small Cap Conference Sept. 30 Benzinga

07:30AM EDT KemPharm to Present at the Benzinga Healthcare Small Cap Conference GlobeNewswire Inc

Sep 23, 2021

07:43AM EDT KemPharm To Present At Cantor Fitzgerald Virtual Global Healthcare Conference Sept. 28 Benzinga

07:30AM EDT KemPharm to Present at the Cantor Fitzgerald Virtual Global GlobeNewswire Inc

Sep 9, 2021

07:30AM EDT KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual GlobeNewswire Inc

Aug 18, 2021

04:45PM EDT KemPharm, Inc.(NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the appointment of Tamara A. Seymour to serve on its Board of Directors and as Chair of the Audit Committee. GlobeNewswire Inc

Aug 12, 2021

04:56PM EDT KemPharm Q2 EPS $0.18 Misses $0.22 Estimate, Sales $12.00M Miss $12.10M Estimate Benzinga

04:05PM EDT KemPharm Reports Second Quarter 2021 Financial Results GlobeNewswire Inc

11:47AM EDT KemPharm Option Alert: Aug 20 $10 Calls Sweep (20) near the Ask: 367 @ $0.7 vs 7326 OI; Earnings 8/12 After Close Ref=$9.89 Benzinga

04:14AM EDT Earnings Scheduled For August 12, 2021 Benzinga

Aug 10, 2021

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 5, 2021

07:30AM EDT Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021, 4:30 p.m. ET GlobeNewswire Inc

Jul 21, 2021

08:34AM EDT KemPharm Announces US Launch Of Innovative ADHD Treatment AZSTARYS By Corium, Inc. Benzinga

08:32AM EDT KemPharm Announces U.S. Launch of ADHD Treatment AZSTARYS By Corium Benzinga

08:30AM EDT KemPharm Announces U.S. Launch of Innovative ADHD Treatment GlobeNewswire Inc

Jul 2, 2021

04:35PM EDT KemPharm Files For Mixed Securities Shelf Offering Of Up To $350M Benzinga

Jun 23, 2021

12:30PM EDT KemPharm Option Alert: Feb 18 $25 Calls Sweep (15) near the Ask: 321 @ $2.2 vs 0 OI; Earnings 8/11 After Close [est] Ref=$14.27 Benzinga

Jun 18, 2021

09:17AM EDT KemPharm Announces Exercise Of Existing Warrants, Highlights Issuance Of Warrants In Private Placement Benzinga

09:15AM EDT KemPharm Announces Exercise of Existing Warrants and Issuance of GlobeNewswire Inc

Jun 16, 2021

07:31AM EDT KemPharm Issues Letter To Shareholders Benzinga

Jun 9, 2021

07:32AM EDT KemPharm to be Added to Russell 2000 and Russell 3000 Indexes Effective June 28, 2021 Benzinga

07:30AM EDT KemPharm to be Added to Russell 2000 and Russell GlobeNewswire Inc

Jun 3, 2021

07:30AM EDT KemPharm Executives to Participate in Panel Discussions During GlobeNewswire Inc

May 26, 2021

07:43AM EDT KemPharm, Inc. Announces Orange Book Listing For Six Patents Covering Serdexmethylphenidate And Confirmation Of NCE Status Benzinga

07:30AM EDT SDX is KemPharms proprietary prodrug of d-methylphenidate (d-MPH) and the primary active pharmaceutical ingredient (API) in AZSTARYS GlobeNewswire Inc

May 13, 2021

04:45PM EDT KemPharm Q1 EPS $(0.54) Misses $(0.17) Estimate, Sales $12.10M Beat $2.10M Estimate Benzinga

04:05PM EDT KemPharm Reports First Quarter 2021 Financial Results GlobeNewswire Inc

04:15AM EDT Earnings Scheduled For May 13, 2021 Benzinga

May 7, 2021

07:33AM EDT KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified As A Schedule IV Controlled Substance By The DEA Benzinga

07:30AM EDT KP879, KemPharms Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If Approved by the FDA GlobeNewswire Inc

Apr 22, 2021

08:09AM EDT The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs Benzinga

Apr 21, 2021

04:46PM EDT KemPharm Confirms Receipt Of $10M Milestone Payment For FDA Approval Of AZSTARYS Per License Agreement With Affiliate Of Gurnet Point Capital Benzinga

04:45PM EDT Eligible to Receive Additional Near-Term $10 Million Milestone Payment Following DEA Scheduling of SDX GlobeNewswire Inc

Apr 14, 2021

10:38AM EDT KemPharm, Inc. (KMPH) shares are rising more than 5 percent on Wednesday morning trade. There were no specific announcements from the company to influence the stock movement. Currently, the shares are at $9.18, up 6.13 percent from the previous close of $8.65. For the 52-week period, the shares have traded in a range of $1.94-$22.08 on average volume of 4,389,496. RTTNews

Apr 9, 2021

08:00AM EDT 10 Biggest Price Target Changes For Friday Benzinga

07:22AM EDT HC Wainwright & Co. Maintains Neutral on KemPharm, Lowers Price Target to $10 Benzinga

07:00AM EDT KemPharm Amends Licensing Agreement With Gurnet Point Capital, Increases Milestone Payments To $590M Benzinga

Apr 8, 2021

04:08PM EDT KemPharm Reports Amendment To Licensing Deal With Gurnet Point Capital Affiliate: Increases Total Potential Regulatory, Sales Milestone Payments To $590M Benzinga

04:05PM EDT Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million, and Adds a New Top-Level Tier for Royalties on U.S. Net Sales GlobeNewswire Inc

Mar 15, 2021

03:21PM EDT KemPharm Option Alert: Fri $17.5 Calls at the Ask: 472 @ $0.8 vs 3029 OI; Earnings 5/11 After Close [est] Ref=$12.25 Benzinga

Mar 11, 2021

04:37PM EST KemPharm FY EPS $(1.07) Misses $(0.64) Estimate, Sales $2.40M Beat $2.00M Estimate Benzinga

04:25PM EST KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results GlobeNewswire Inc

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

03:35AM EST Earnings Scheduled For March 11, 2021 Benzinga

Mar 9, 2021

07:30AM EST Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET GlobeNewswire Inc

Mar 8, 2021

01:39PM EST After Months Of Volatile Trading, A Confident Start To March Benzinga

Mar 4, 2021

04:41PM EST KemPharm to Present at the 33rd Annual Roth Conference GlobeNewswire Inc

10:10AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 4, 2021 Benzinga

06:17AM EST HC Wainwright & Co. Downgrades KemPharm to Neutral, Adjusts Price Target to $12 Benzinga

Mar 3, 2021

02:30PM EST Mid-Afternoon Market Update: Nasdaq Falls Over 300 Points; Veritiv Shares Surge Benzinga

12:13PM EST Mid-Day Market Update: Crude Oil Surges 3%; KemPharm Shares Spike Higher Benzinga

10:17AM EST Mid-Morning Market Update: Markets Mostly Lower; Dollar Tree Reports Mixed Q4 Results Benzinga

09:55AM EST Shares of KemPharm, Inc. (KMPH) are surging over 70% on Wednesday morning after the US Food and Drug Administration approved its treatment for attention deficit hyperactivity disorder in patients age six years and older. RTTNews

07:46AM EST The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study Benzinga

05:05AM EST KemPharm Shares Trade Higher After FDA Approval For Azstarys In ADHD Benzinga

Mar 2, 2021

11:48PM EST KemPharma Announces FDA Approval of AZSTARYS Benzinga

11:46PM EST KemPharm: FDA Approves AZSTARYS For Attention Deficit Hyperactivity Disorder In Patients Age Six Years And Older RTTNews

11:32PM EST Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET GlobeNewswire Inc

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

Feb 28, 2021

11:38AM EST Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 9, 2021

04:55PM EST Kempharm S-3 Shows Registration For ~7.94M Share Common Stock Shelf Offering Benzinga

Jan 27, 2021

08:42AM EST KemPharm Receives FDA Clearance To Initiate KP879 Clinical Program For Stimulant Use Disorder RTTNews

08:30AM EST KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program GlobeNewswire Inc

Jan 26, 2021

05:20PM EST Kempharm Inc Files For Offering Of Up To 6.8M Shares Of Common Stock Benzinga

Jan 25, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 25, 2021 Benzinga

07:55AM EST Roth Capital Initiates Coverage On KemPharm with Buy Rating, Announces Price Target of $28 Benzinga

Jan 14, 2021

07:30AM EST Combination of Oral and Poster Presentations Scheduled for January 15, 2021 GlobeNewswire Inc

Jan 13, 2021

04:19PM EST Kempharm S-3 Shows Registration For ~8.47M Common Stock Shelf Offering Benzinga

07:30AM EST KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the company is participating in BIO @ JPM and Fierce JPM Week 2021. Both events are being held virtually during the month of January alongside the J.P. Morgan 39th Annual Healthcare Conference 2021. GlobeNewswire Inc

Jan 8, 2021

08:34AM EST KemPharm Announces Pricing Of $50M Offering At $6.50/Share Benzinga

08:30AM EST Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol KMPH today, January 8, 2021 GlobeNewswire Inc

Dec 23, 2020

06:11PM EST KemPharm Announces 1-for-16 Reverse Stock Split GlobeNewswire Inc

Dec 22, 2020

07:30AM EST KemPharm Files IND for KP879 for the Treatment of Stimulant Use GlobeNewswire Inc

Dec 2, 2020

07:30AM EST KemPharm Participates in KP415 Late-Cycle Communication Meeting GlobeNewswire Inc

Nov 30, 2020

07:30AM EST Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET GlobeNewswire Inc

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

Nov 23, 2020

04:30PM EST IND for KP879 Expected to be Filed Before Year-End 2020; New Prodrug CandidateAdded to Pipeline,Targeting Rare CNS Disease, Idiopathic Hypersomnia (IH) GlobeNewswire Inc

Nov 18, 2020

08:30AM EST Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET GlobeNewswire Inc

Oct 29, 2020

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 26, 2020

08:30AM EDT Special Meeting of Stockholders Rescheduled to Tuesday, Nov 17, 2020, 8:00 a.m. ET GlobeNewswire Inc

Oct 22, 2020

07:30AM EDT KemPharms KP415 and Serdexmethylphenidate (SDX) GlobeNewswire Inc

Oct 5, 2020

08:46AM EDT KemPharm and Corium Expand Relationship with New Consultation GlobeNewswire Inc

Sep 25, 2020

05:00PM EDT KemPharm Files Preliminary Proxy for Special Meeting of Stockholders GlobeNewswire Inc

Sep 14, 2020

08:35AM EDT Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com GlobeNewswire Inc

Sep 8, 2020

12:08PM EDT 2 Conferences Are Going Virtual This Month One On Cannabis And Another Life Sciences Benzinga

Sep 2, 2020

04:05PM EDT KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at two investor conferences during the month of September. GlobeNewswire Inc

Aug 14, 2020

07:30AM EDT KemPharm Participates in KP415 Mid-Cycle Communication Meeting GlobeNewswire Inc

Aug 12, 2020

04:05PM EDT Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET GlobeNewswire Inc

04:21AM EDT Earnings Scheduled For August 12, 2020 Benzinga

Aug 4, 2020

07:30AM EDT KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast onWednesday, August 12, 2020, at 4:30 p.m. ET, to discuss its corporate and financial results for the second quarter 2020. GlobeNewswire Inc

Jul 28, 2020

07:30AM EDT New Patent Issuance Extends SDX Patent Life for an Additional Five Years until 2037 GlobeNewswire Inc

Share